BR0211474A - Uso de tat de hiv-1 biologicamente ativa, fragmentos ou derivadas desta, para atingir e/ou ativar células apresentadoras de antìgeno, e/ou para disponibilizar moléculas carga para vacinação e/ou tratamento preventivo ou terapêutico de outras doenças - Google Patents
Uso de tat de hiv-1 biologicamente ativa, fragmentos ou derivadas desta, para atingir e/ou ativar células apresentadoras de antìgeno, e/ou para disponibilizar moléculas carga para vacinação e/ou tratamento preventivo ou terapêutico de outras doençasInfo
- Publication number
- BR0211474A BR0211474A BR0211474-7A BR0211474A BR0211474A BR 0211474 A BR0211474 A BR 0211474A BR 0211474 A BR0211474 A BR 0211474A BR 0211474 A BR0211474 A BR 0211474A
- Authority
- BR
- Brazil
- Prior art keywords
- tat
- biologically active
- fragments
- derivatives
- cells
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 4
- 239000012634 fragment Substances 0.000 title abstract 4
- 201000010099 disease Diseases 0.000 title abstract 3
- 230000001225 therapeutic effect Effects 0.000 title abstract 3
- 238000002255 vaccination Methods 0.000 title abstract 3
- 210000000612 antigen-presenting cell Anatomy 0.000 title abstract 2
- 230000003449 preventive effect Effects 0.000 title abstract 2
- 239000000427 antigen Substances 0.000 abstract 6
- 102000036639 antigens Human genes 0.000 abstract 6
- 108091007433 antigens Proteins 0.000 abstract 6
- 208000030507 AIDS Diseases 0.000 abstract 2
- 208000035473 Communicable disease Diseases 0.000 abstract 2
- 241000725303 Human immunodeficiency virus Species 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 101710149951 Protein Tat Proteins 0.000 abstract 2
- 239000002671 adjuvant Substances 0.000 abstract 2
- 230000002491 angiogenic effect Effects 0.000 abstract 2
- 210000004027 cell Anatomy 0.000 abstract 2
- 210000004443 dendritic cell Anatomy 0.000 abstract 2
- 210000002889 endothelial cell Anatomy 0.000 abstract 2
- 230000028993 immune response Effects 0.000 abstract 2
- 230000002757 inflammatory effect Effects 0.000 abstract 2
- 210000002540 macrophage Anatomy 0.000 abstract 2
- 108010070875 Human Immunodeficiency Virus tat Gene Products Proteins 0.000 abstract 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 230000035800 maturation Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 230000001681 protective effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
- C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Ophthalmology & Optometry (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Emergency Medicine (AREA)
Abstract
"USO DE TAT DE HIV-1 BIOLOGICAMENTE ATIVA, FRAGMENTOS OU DERIVADAS DESTA, PARA ATINGIR E/OU ATIVAR CéLULAS APRESENTADORAS DE ANTìGENO, E/OU PARA DISPONIBILIZAR MOLéCULAS CARGA PARA VACINAçãO E/OU TRATAMENTO PREVENTIVO OU TERAPêUTICO DE OUTRAS DOENçAS". A presente invenção refere-se a um método para a vacinação profilática e/ou terapêutica e/ou tratamento e/ou diagnóstico de HIV/AIDS, outras doenças infecciosas, doenças inflamatórias e angiogênicas e tumores, que utiliza uma proteína Tat biologicamente ativa de HIV-1, fragmentos ou derivados desta, como um módulo com uma ou mais das seguintes características: antígeno, adjuvante e sistema de direcionamento-disponibilização para células apresentadoras de antígeno específicas incluindo células dendríticas, células endoteliais e macrófagos. Em particular, é reivindicado o fato de Tat poder ser utilizada apenas em sua forma biologicamente ativa como um antígeno combinada com um ou mais outros antígenos, para estimular e amplificar respostas imune protetoras contra si mesma bem como outros antígenos e/ou para seletivamente disponibilizar este(s) antígeno(s) bem como compostos ativos para células dendríticas, células endoteliais e macrófagos, devido a sua capacidade de atingir estas APCs e de ativar sua maturação e funções e de aumentar respostas imune do tipo Th-1 como um adjuvante. Por esta razão, devido a estas características e à distribuição destas células no corpo (durante distúrbios fisiológicos e patológicos), Tat biologicamente ativa, fragmentos ou derivados desta, contendo a região RGD, pode ser utilizada para propósitos preventivos, terapêuticos e/ou de diagnósticos para HIV/AIDS, outras doenças infecciosas, doenças inflamatórias e angiogênicas e tumores.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP01118114A EP1279404A1 (en) | 2001-07-26 | 2001-07-26 | Use of HIV-1 tat, fragments or derivatives thereof, to target or to activate antigen-presenting cells, to deliver cargo molecules for vaccination or to treat other diseases |
PCT/EP2002/008377 WO2003009867A1 (en) | 2001-07-26 | 2002-07-26 | Use of biologically active hiv-1 tat, fragments or derivates thereof, to target and/or to activate antigen-presenting cells, and/or to deliver cargo molecules for preventive or therapeutic vaccination and/or to treat other diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0211474A true BR0211474A (pt) | 2004-07-13 |
Family
ID=8178141
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0211474-7A BR0211474A (pt) | 2001-07-26 | 2002-07-26 | Uso de tat de hiv-1 biologicamente ativa, fragmentos ou derivadas desta, para atingir e/ou ativar células apresentadoras de antìgeno, e/ou para disponibilizar moléculas carga para vacinação e/ou tratamento preventivo ou terapêutico de outras doenças |
Country Status (19)
Country | Link |
---|---|
US (1) | US7811573B2 (pt) |
EP (2) | EP1279404A1 (pt) |
JP (1) | JP5134183B2 (pt) |
CN (1) | CN1318091C (pt) |
AP (1) | AP2004002986A0 (pt) |
AT (1) | ATE510558T1 (pt) |
AU (1) | AU2002331350B2 (pt) |
BR (1) | BR0211474A (pt) |
CA (1) | CA2455227C (pt) |
DK (1) | DK1425035T3 (pt) |
EA (1) | EA006850B1 (pt) |
ES (1) | ES2367255T3 (pt) |
HU (1) | HUP0400660A2 (pt) |
IL (1) | IL160015A0 (pt) |
MX (1) | MXPA04000287A (pt) |
NZ (1) | NZ531364A (pt) |
OA (1) | OA12701A (pt) |
PL (1) | PL368243A1 (pt) |
WO (1) | WO2003009867A1 (pt) |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0323840D0 (en) * | 2003-10-10 | 2003-11-12 | Ist Superiore Sanita | Vaccines |
GB0405480D0 (en) | 2004-03-11 | 2004-04-21 | Istituto Superiore Di Sanito | Novel tat complexes,and vaccines comprising them |
US7927580B2 (en) | 2004-03-16 | 2011-04-19 | Nanirx, Inc. | Tat-based immunomodulatory compositions and methods of their discovery and use |
WO2007001448A2 (en) | 2004-11-04 | 2007-01-04 | Massachusetts Institute Of Technology | Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals |
CN100429228C (zh) * | 2005-06-17 | 2008-10-29 | 中国人民解放军第三军医大学第三附属医院 | 重组人a20蛋白及其用途 |
US9267937B2 (en) | 2005-12-15 | 2016-02-23 | Massachusetts Institute Of Technology | System for screening particles |
JP2009534309A (ja) | 2006-03-31 | 2009-09-24 | マサチューセッツ インスティテュート オブ テクノロジー | 治療剤の標的化送達のためのシステム |
JP5630998B2 (ja) | 2006-05-15 | 2014-11-26 | マサチューセッツ インスティテュート オブ テクノロジー | 機能的粒子のためのポリマー |
WO2007150030A2 (en) | 2006-06-23 | 2007-12-27 | Massachusetts Institute Of Technology | Microfluidic synthesis of organic nanoparticles |
CA2660830A1 (en) * | 2006-08-14 | 2008-02-21 | Gideon Goldstein | Compositions and methods for the treatment and prophylaxis of multiple strains and subtypes of hiv-1 |
WO2008098165A2 (en) | 2007-02-09 | 2008-08-14 | Massachusetts Institute Of Technology | Oscillating cell culture bioreactor |
JP2010523595A (ja) | 2007-04-04 | 2010-07-15 | マサチューセッツ インスティテュート オブ テクノロジー | ポリ(アミノ酸)ターゲッティング部分 |
US10736848B2 (en) | 2007-10-12 | 2020-08-11 | Massachusetts Institute Of Technology | Vaccine nanotechnology |
GB0802224D0 (en) | 2008-02-06 | 2008-03-12 | Inst Superiore Di Sanito | Process for the production of vaccine components |
EP2247330B1 (en) | 2008-02-07 | 2017-09-20 | The University of Washington | Circumferential aerosol device |
EP2106803A1 (en) * | 2008-04-04 | 2009-10-07 | Fondazione Centro San Raffaele del Monte Tabor | Method to design and uses of overlapping peptides for monitoring T-cell responses in HIV patients |
US9439922B2 (en) | 2008-05-14 | 2016-09-13 | Jawaharlal Nehru Centre For Advanced Scientific Research | Tat DNA sequences, gene constructs, vaccine and processes thereof |
US8591905B2 (en) | 2008-10-12 | 2013-11-26 | The Brigham And Women's Hospital, Inc. | Nicotine immunonanotherapeutics |
US8277812B2 (en) | 2008-10-12 | 2012-10-02 | Massachusetts Institute Of Technology | Immunonanotherapeutics that provide IgG humoral response without T-cell antigen |
US8343497B2 (en) * | 2008-10-12 | 2013-01-01 | The Brigham And Women's Hospital, Inc. | Targeting of antigen presenting cells with immunonanotherapeutics |
US8343498B2 (en) | 2008-10-12 | 2013-01-01 | Massachusetts Institute Of Technology | Adjuvant incorporation in immunonanotherapeutics |
NZ595060A (en) | 2009-03-23 | 2013-05-31 | Pin Pharma Inc | Treatment of cancer with immunostimulatory hiv tat derivative polypeptides |
CA2790426A1 (en) * | 2010-02-18 | 2011-08-25 | Emory University | Vectors expressing hiv antigens and gm-csf and related methods for generating an immune response |
US20110287045A1 (en) * | 2010-05-20 | 2011-11-24 | Zongdong Li | Enhanced immune response against infections |
BR112013022249B8 (pt) | 2011-03-03 | 2022-10-25 | Impel Neuropharma Inc | Dispositivo de distribuição de droga nasal |
BR112013028572B8 (pt) | 2011-05-09 | 2022-10-25 | Impel Neuropharma Inc | Bocais para distribuição de droga nasal |
JP6306593B2 (ja) * | 2012-09-13 | 2018-04-04 | ユニベルシテ ドゥ ジュネーブ | 細胞透過性ペプチド |
CN103880961A (zh) * | 2012-12-19 | 2014-06-25 | 邱书奇 | 一种诱导免疫耐受融合肽构建 |
EP2991713B1 (en) | 2013-04-28 | 2019-06-19 | Impel Neuropharma Inc. | Medical unit dose container |
AU2014329393B2 (en) | 2013-10-04 | 2020-04-30 | Pin Pharma, Inc. | Immunostimulatory HIV Tat derivative polypeptides for use in cancer treatment |
ES2804750T3 (es) | 2014-04-24 | 2021-02-09 | Janssen Sciences Ireland Unlimited Co | Uso de una proteína accesoria derivada del VIH para la reactivación del VIH latente |
JP6753927B2 (ja) | 2015-09-10 | 2020-09-09 | インペル ニューロファーマ インコーポレイテッド | 直列形経鼻送達デバイス |
CN116064669A (zh) | 2016-01-08 | 2023-05-05 | 吉奥瓦科斯公司 | 用于产生对肿瘤相关抗原的免疫应答的组合物和方法 |
CN105535937B (zh) * | 2016-03-11 | 2018-03-13 | 刘红 | 一种用于治疗类风湿性关节炎的皮下注射用原位凝胶 |
WO2018050225A1 (en) * | 2016-09-15 | 2018-03-22 | Yu Di | T-cell immunotherapy |
US11311612B2 (en) | 2017-09-19 | 2022-04-26 | Geovax, Inc. | Compositions and methods for generating an immune response to treat or prevent malaria |
KR102131898B1 (ko) * | 2017-10-31 | 2020-07-08 | 주식회사 노벨티노빌리티 | Scf 및 갈렉틴-1을 표적으로 하는 이중표적항체 및 그 용도 |
JP2021503988A (ja) | 2017-11-21 | 2021-02-15 | インペル ニューロファーマ インコーポレイテッド | インレットインターフェースを用いた鼻腔内装置 |
EP3713628A4 (en) | 2017-11-21 | 2021-08-18 | Impel Neuropharma Inc. | INTRA-NASAL DEVICE WITH DIVER TUBE |
CN111836615A (zh) | 2018-01-05 | 2020-10-27 | 英倍尔药业股份有限公司 | 通过精密鼻装置的奥氮平的鼻内递送 |
ES2937440T3 (es) | 2018-01-05 | 2023-03-28 | Impel Pharmaceuticals Inc | Administración intranasal de dihidroergotamina mediante un dispositivo olfativo de precisión |
KR20210034047A (ko) | 2018-07-19 | 2021-03-29 | 임펠 뉴로파마 인코포레이티드 | 파킨슨 병 치료를 위한 레보도파 및 도파 데카르복실라아제 저해제의 기도 전달 |
EA202191856A1 (ru) | 2019-01-03 | 2021-09-02 | Импел Ньюрофарма, Инк. | Устройство для назальной доставки лекарственных средств |
WO2020141608A1 (ja) * | 2019-01-04 | 2020-07-09 | 国立大学法人京都大学 | 潰瘍性大腸炎及び原発性硬化性胆管炎の検査方法 |
EP3969085A4 (en) | 2019-05-17 | 2023-06-21 | Impel Pharmaceuticals Inc. | DISPOSABLE NASAL DELIVERY DEVICE |
WO2020246584A1 (ja) * | 2019-06-06 | 2020-12-10 | デンカ株式会社 | ペプチド核酸を基盤としたアジュバント |
CN111450082A (zh) * | 2020-04-26 | 2020-07-28 | 天津大学 | 一种系统性红斑狼疮治疗纳米颗粒的合成方法 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9720585D0 (en) * | 1997-09-26 | 1997-11-26 | Smithkline Beecham Biolog | Vaccine |
IT1297090B1 (it) * | 1997-12-01 | 1999-08-03 | Barbara Ensoli | Tat di hiv-1 o suoi derivati, da soli od in combinazione, a scopo vaccinale, profilattico e terapeutico, contro l'aids i tumori e le |
FI105105B (fi) * | 1998-02-27 | 2000-06-15 | Finnish Immunotechnology Ltd O | Itsereplikoiva DNA-vektori immunisoimiseksi HIV:ta vastaan |
WO2000078969A1 (en) * | 1999-06-21 | 2000-12-28 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Hiv tat peptides and multiple peptide conjugate system |
CA2376992A1 (en) | 1999-06-29 | 2001-01-04 | Smithkline Beecham Biologicals S.A. | Use of cpg as an adjuvant for hiv vaccine |
WO2001012220A1 (en) | 1999-08-12 | 2001-02-22 | Cohen David I | Non-immunosuppressant hiv tat |
AU7577600A (en) * | 1999-09-13 | 2001-04-17 | Cornell Research Foundation Inc. | Delivering to eucaryotic cells bacterial proteins that are secreted via type iiisecretion systems |
AP2002002592A0 (en) | 2000-01-31 | 2002-09-30 | Smithkline Beecham Biolog | Vaccine for the prophylactic or therapeutic immunization against HIV. |
AU2001234616A1 (en) | 2000-01-31 | 2001-08-07 | Vic Jira | Vaccine composition, process and methods |
US6544780B1 (en) | 2000-06-02 | 2003-04-08 | Genphar, Inc. | Adenovirus vector with multiple expression cassettes |
AT410635B (de) * | 2000-10-18 | 2003-06-25 | Cistem Biotechnologies Gmbh | Vakzin-zusammensetzung |
-
2001
- 2001-07-26 EP EP01118114A patent/EP1279404A1/en not_active Withdrawn
-
2002
- 2002-07-26 EP EP02767265A patent/EP1425035B1/en not_active Expired - Lifetime
- 2002-07-26 CN CNB028146581A patent/CN1318091C/zh not_active Expired - Fee Related
- 2002-07-26 OA OA1200400015A patent/OA12701A/en unknown
- 2002-07-26 EA EA200400227A patent/EA006850B1/ru not_active IP Right Cessation
- 2002-07-26 AP APAP/P/2004/002986A patent/AP2004002986A0/en unknown
- 2002-07-26 AU AU2002331350A patent/AU2002331350B2/en not_active Ceased
- 2002-07-26 BR BR0211474-7A patent/BR0211474A/pt not_active IP Right Cessation
- 2002-07-26 NZ NZ531364A patent/NZ531364A/en not_active IP Right Cessation
- 2002-07-26 ES ES02767265T patent/ES2367255T3/es not_active Expired - Lifetime
- 2002-07-26 WO PCT/EP2002/008377 patent/WO2003009867A1/en active IP Right Grant
- 2002-07-26 AT AT02767265T patent/ATE510558T1/de not_active IP Right Cessation
- 2002-07-26 DK DK02767265.8T patent/DK1425035T3/da active
- 2002-07-26 US US10/485,180 patent/US7811573B2/en not_active Expired - Fee Related
- 2002-07-26 IL IL16001502A patent/IL160015A0/xx not_active IP Right Cessation
- 2002-07-26 CA CA2455227A patent/CA2455227C/en not_active Expired - Fee Related
- 2002-07-26 MX MXPA04000287A patent/MXPA04000287A/es not_active Application Discontinuation
- 2002-07-26 HU HU0400660A patent/HUP0400660A2/hu unknown
- 2002-07-26 PL PL02368243A patent/PL368243A1/xx unknown
- 2002-07-26 JP JP2003515259A patent/JP5134183B2/ja not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US20050036985A1 (en) | 2005-02-17 |
EP1279404A1 (en) | 2003-01-29 |
US7811573B2 (en) | 2010-10-12 |
HUP0400660A2 (hu) | 2005-01-28 |
IL160015A0 (en) | 2004-06-20 |
EA006850B1 (ru) | 2006-04-28 |
EP1425035B1 (en) | 2011-05-25 |
EP1425035A1 (en) | 2004-06-09 |
ES2367255T3 (es) | 2011-10-31 |
WO2003009867A1 (en) | 2003-02-06 |
PL368243A1 (en) | 2005-03-21 |
ATE510558T1 (de) | 2011-06-15 |
AU2002331350B2 (en) | 2008-06-12 |
JP2005505520A (ja) | 2005-02-24 |
CN1533284A (zh) | 2004-09-29 |
MXPA04000287A (es) | 2005-03-07 |
CA2455227A1 (en) | 2003-02-06 |
EA200400227A1 (ru) | 2004-06-24 |
NZ531364A (en) | 2005-12-23 |
OA12701A (en) | 2006-06-23 |
JP5134183B2 (ja) | 2013-01-30 |
DK1425035T3 (da) | 2011-08-29 |
CA2455227C (en) | 2012-01-24 |
CN1318091C (zh) | 2007-05-30 |
AP2004002986A0 (en) | 2004-03-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0211474A (pt) | Uso de tat de hiv-1 biologicamente ativa, fragmentos ou derivadas desta, para atingir e/ou ativar células apresentadoras de antìgeno, e/ou para disponibilizar moléculas carga para vacinação e/ou tratamento preventivo ou terapêutico de outras doenças | |
Lee et al. | Anti-inflammatory effect of bee venom on type II collagen-induced arthritis | |
Bakalash et al. | Antigenic specificity of immunoprotective therapeutic vaccination for glaucoma | |
HUP0202779A2 (hu) | Immunológiai eljárás szöveti transzglutamináz (tTG) elleni antitestek kimutatására, tTG alkalmazása diagnosztikai célokra és terápiás ellenőrzésre, valamint tTG-t tartalmazó orális gyógyászati hatóanyag | |
Mizrahi et al. | The tissue-specific self-pathogen is the protective self-antigen: the case of uveitis | |
ES2384278T3 (es) | IL-1-alfa para su uso en un procedimiento de tratamiento de placas ateroscleróticas | |
NO20071267L (no) | Forhindring og behandling av synukleinopatiske og amyloidogene sykdommer | |
TR200103447T2 (tr) | Amiloidojenik hastalığın önlenmesi ve tedavisi | |
TR200001608T2 (tr) | Amiloidojenik hastalığın önlenmesi ve tedavisi | |
ES2205231T3 (es) | Procedimiento de tratamiento de la hipersensibilidad de tipo i que utilizan monofosforil lipido a. | |
JP2009106764A (ja) | 電磁放射線治療法 | |
KR930702026A (ko) | 자기항원의 경구 투여에 의한 자기면역 질병의 치료 | |
AR041725A1 (es) | Prevencion, tratamiento de la enfermedad sinucleinopatica y composicion farmacologica | |
CR9968A (es) | Metodos y composiciones para usarse en el tratamiento de pacientes con enfermedades de autoanticuerpo positivo | |
AU2006222717A1 (en) | Improved vaccine | |
BR0211049A (pt) | Método de tratamento ou prevenção de doenças ou disfunções e uso de mycoplasma hyopneumoniae | |
CA2688766C (en) | Compositions and methods for treatment of multiple sclerosis | |
Horner et al. | Optimized conjugation ratios lead to allergen immunostimulatory oligodeoxynucleotide conjugates with retained immunogenicity and minimal anaphylactogenicity | |
ES2181676T3 (es) | Diagnosis y tratamiento de enfermedades autoinmunitarias. | |
SA519410007B1 (ar) | مركبات ببتيد وطرق لمعالجة السكر | |
ES2315371T3 (es) | Uso de poli-glu,tyr para terapia neuroprotectora del snc o snp. | |
CY1115407T1 (el) | Θοριο-227 για χρηση στην ακτινοθεραπεια ασθενειων των μαλακων ιστων | |
HU228207B1 (hu) | Vakcina és eljárás mozgatóneuron-betegségek kezelésére | |
WO2002094199A3 (en) | METHOD OF INCREASING ANTI-NeuGc ANTIBODY LEVELS IN BLOOD | |
Rudy | Imiquimod (Aldara): modifying the immune response |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE 5A., 6A., E 7A. ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2029 DE 24/11/2009. |